ClinicalTrials.gg
CompletedNCT02785133Updated Oct 26, 2016

Safety and Feasibility of Polychromatic Light Emitting Diode for Peripheral Catheter Illumination During Peripheral Intravenous Delivery of Normal Saline

An interventional study of UVL1000 Treatment Station and Normal Saline Solution in Quality of Life and Fatigue, sponsored by UVLrx Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-26.

Sponsored by UVLrx Therapeutics · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,063
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 704 studies in Fatigue with a site in United States — 91 open to participants now, 113 under way, 10 of them phase 3. Fatigue · United States.

Enrollment
4th of 610
3,063 · median 47
Started
2014
with 31 others
No phase
414 of 704
56 open now
Registered
348th of 704
by date

Among the 704 studies in Fatigue with a site in United States, this one is the 4th largest by enrollment of the 610 interventional ones that give a count, is one of 32 that started in 2014, is one of 414 with no phase, and was the 348th registered.

Fatigue

2,232 studies on the registry are indexed under Fatigue; 427 are open to participants now.

Browse Fatigue studies →

Open to participants now

91 of the 704 studies in Fatigue with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 239 Fatigue studies recruiting now, 111 (46%) set no upper age limit and 98 (41%) stop at 75 or younger; 23 take children under 18; 73 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 704 studies in Fatigue with a site in United States, or all of them as a file.
02

Study summary

This study uses a prospective non-randomized, non-controlled design. Five-hundred (500) subjects having previously received a peripheral intravenous therapy will be enrolled into a single treatment group. The purpose of the study is to evaluate the safety, feasibility, and improved energy levels following treatment with a low-light source integrated into an existing peripheral intravascular catheter. The absence of a control group is based on the following reason:This is a pilot investigation to establish a baseline understanding of the safety, feasibility, and cursory utility of polychromatic light emitting diodes integrated into an existing 20-gauge 1.0 inch intravenous catheter to improve self-reported overall subject energy levels.

Read the detailed description

This study uses a prospective non-randomized, non-controlled design. Five-hundred (500) subjects having previously received a peripheral intravenous therapy will be enrolled into a single treatment group. The purpose of the study is to evaluate the safety, feasibility, and cursory utility of a low-light source integrated into an existing peripheral intravenous catheter. The absence of a control group is based on the following reason: This is a pilot investigation to establish a baseline understanding of the safety, feasibility, and cursory utility of polychromatic light emitting diodes integrated into an existing 20-gauge 1.0 inch peripheral intravascular catheter to improve self-reported overall subject energy levels based on the change in Epworth Sleepiness scores.

Peripheral intravascular therapy has been used for decades as an effective therapy to maintain proper hydration and electrolyte levels, and has been deemed a non-significant medical procedure. Peripheral intravascular therapy can be infused with various molecular agents such as supplements (Vitamin B12) for the purpose of improving energy levels and overall quality of life. However, the use of normal saline as a standard alone helps improve hydration and cell function. Low-energy light therapy has been established as an alternative treatment for a myriad of medical conditions. Light-based therapy stimulates photoreceptors found within cells and can improve overall cellular bioenergetics. The concurrent administration of low-light therapy and peripheral intravascular normal saline therapy may serve as a viable therapy for the treatment for improvement in subject quality of life and energy levels Accordingly, this study is designed to assess the safety, feasibility, and cursory improvement in self-reported energy levels following intervention of low-light therapy integrated into a standard peripheral intravascular catheter.

03

Conditions studied

  • Quality of Life
  • Fatigue

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily signed form
  • Ages 18-70
  • Completed urine pregnancy examination with negative result
  • Self-reported energy level of >4 on the Epworth sleepiness test
  • No breastfeeding for 3 months prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Active infection along potential intravenous catheter sites
  • Pacemaker
  • Currently taking prescription blood thinning medications (i.e. Warfarin)
  • Suffering from a chronic, progressive blood disorder, such as blood cancer (Thalassemia, Lymphoma, Myeloma, etc.)
  • Use of anti-inflammatory medications on a chronic basis (i.e. ibuprofen, aspirin, and )
  • Suffering from blood clotting disorders (hypercoagulable condition, thrombocytosis, etc.)
  • anxiety and/or depression
  • Participated in a clinical study in the last 30 days
  • Clinical Cardiac Disease
  • Active Infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3,063 participants (actual)

Study arms

  • Experimental
    Treatment group

    Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by a light emitting diode. Small adapter attaches directly to a standard 20-gauge catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the distal end of the catheter. Polychromatic light is emitted to illuminate the catheter and site of catheter entrance. Concurrently, normal saline flows through the optic adapter and through into the 20-gauge catheter.

    Device: UVL1000 Treatment Station · Drug: Normal Saline Solution · Device: Peripheral Catheterization

Interventions

  • DeviceUVL1000 Treatment Station

    Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0" catheter

  • 150 ml of 0.9% Sodium Chloride Solution

  • DevicePeripheral Catheterization

    20-gauge 1.0" catheter

06

What researchers measure

Primary outcomes

  1. The use of polychromatic light therapy delivered through an intravascular catheter for the improvement in self-reported subject energy levels

    The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. It has become the world standard method for making this assessment. The Epworth Sleepiness Scale will be used to evaluate subject energy levels at both baseline and post-procedure administration phase. Subjects will rate, on a 4-point scale (0 - 3), their usual chances of dozing off or falling asleep in 8 different situations or activities that most people engage in as part of their daily lives, although not necessarily every day. It evaluates what the chances are that they would doze off whenever they were in each situation.

    Time frame: Baseline and 10 weeks

Secondary outcomes

  1. The improvement in subject quality of life using a five (5)-point GRA

    Descriptive scale evaluating subject's perceived quality of life following treatment administration scale

    Time frame: 10 weeks

  2. Subject satisfaction based on five (5)-point satisfaction questionnaire

    Self-reported overall treatment satisfaction based on perceived response from treatment

    Time frame: 10 weeks

07

Study locations

1 site
  • Lozano Medical Clinic
    Dallas, Texas 75218, United States
08

References and documents

Individual participant data

Plan to share: Undecided — At this juncture, there is no specific plan to share data with any regulatory agency for the purposes of 510k market clearance or there is no determination at this juncture to present data to the medical community (i.e. peer-reviewed publication of medical conference)

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
May 27, 2016
Start
Dec 2014
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Last update
Oct 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02785133
Lead sponsor
UVLrx Therapeutics
Responsible party
Sponsor
First posted
May 27, 2016
Start date
Dec 2014
Primary completion
Oct 2016
Completion
Oct 2016
Last update
Oct 26, 2016

Study contacts

Ryan J Maloney
study director · Maloney Insights

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saline Solution

Start the discussion